UBS Group’s Cytosorbents Corp CTSO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $49K | Buy |
6,551
+791
| +14% | +$8.35K | ﹤0.01% | 7578 |
|
|
2026
Q1 | $65.2K | Sell |
5,760
-4
| -0.1% | -$55 | ﹤0.01% | 7224 |
|
|
2025
Q4 | $73.7K | Buy |
5,764
+4
| +0.1% | +$62 | ﹤0.01% | 7048 |
|
|
2025
Q3 | $108K | Sell |
5,760
-357
| -6% | -$7.03K | ﹤0.01% | 7066 |
|
|
2025
Q2 | $157K | Buy |
6,117
+357
| +6% | +$7.17K | ﹤0.01% | 6894 |
|
|
2025
Q1 | $115K | Sell |
5,760
-1,486
| -21% | -$31.3K | ﹤0.01% | 6946 |
|
|
2024
Q4 | $132K | Buy |
7,246
+7,117
| +5,517% | +$140K | ﹤0.01% | 6704 |
|
|
2024
Q3 | $3.86K | Buy |
129
+36
| +39% | +$790 | ﹤0.01% | 8213 |
|
|
2024
Q2 | $1.3K | Buy |
93
+90
| +3,000% | +$1.56K | ﹤0.01% | 8598 |
|
|
2024
Q1 | $54 | Sell |
3
-145
| -98% | -$2.82K | ﹤0.01% | 8918 |
|
|
2023
Q4 | $3.29K | Buy |
148
+138
| +1,380% | +$4.1K | ﹤0.01% | 7993 |
|
|
2023
Q3 | $370 | Sell |
10
-46
| -82% | -$2.64K | ﹤0.01% | 8544 |
|
|
2023
Q2 | $4.04K | Buy |
56
+32
| +133% | +$2.02K | ﹤0.01% | 7577 |
|
|
2023
Q1 | $1.62K | Sell |
24
-153
| -86% | -$9.18K | ﹤0.01% | 8692 |
|
|
2022
Q4 | $5.5K | Sell |
177
-106
| -37% | -$3.14K | ﹤0.01% | 9171 |
|
|
2022
Q3 | $7K | Buy |
283
+260
| +1,130% | +$10.2K | ﹤0.01% | 8857 |
|
|
2022
Q2 | $1K | Sell |
23
-137
| -86% | -$6.29K | ﹤0.01% | 9841 |
|
|
2022
Q1 | $10K | Sell |
160
-403
| -72% | -$28.9K | ﹤0.01% | 8403 |
|
|
2021
Q4 | $48K | Buy |
563
+483
| +604% | +$54.2K | ﹤0.01% | 6929 |
|
|
2021
Q3 | $13K | Sell |
80
-91
| -53% | -$14.8K | ﹤0.01% | 7658 |
|
|
2021
Q2 | $26K | Sell |
171
-208
| -55% | -$35.1K | ﹤0.01% | 7070 |
|
|
2021
Q1 | $66K | Sell |
379
-12
| -3% | -$2.29K | ﹤0.01% | 6278 |
|
|
2020
Q4 | $62K | Buy |
391
+376
| +2,507% | +$62.9K | ﹤0.01% | 5994 |
|
|
2020
Q3 | $2K | Sell |
15
-659
| -98% | -$119K | ﹤0.01% | 7643 |
|
|
2020
Q2 | $133K | Sell |
674
-759
| -53% | -$139K | ﹤0.01% | 5095 |
|
|
2020
Q1 | $221K | Sell |
1,433
-718
| -33% | -$72.5K | ﹤0.01% | 4645 |
|
|
2019
Q4 | $166K | Buy |
2,151
+917
| +74% | +$80K | ﹤0.01% | 5716 |
|
|
2019
Q3 | $124K | Sell |
1,234
-1,152
| -48% | -$134K | ﹤0.01% | 5623 |
|
|
2019
Q2 | $315K | Buy |
2,386
+629
| +36% | +$86.4K | ﹤0.01% | 4624 |
|
|
2019
Q1 | $266K | Buy |
1,757
+195
| +12% | +$30.4K | ﹤0.01% | 4435 |
|
|
2018
Q4 | $253K | Buy |
1,562
+406
| +35% | +$80.6K | ﹤0.01% | 4772 |
|
|
2018
Q3 | $299K | Sell |
1,156
-620
| -35% | -$155K | ﹤0.01% | 4754 |
|
|
2018
Q2 | $405K | Buy |
1,776
+1,771
| +35,420% | +$335K | ﹤0.01% | 4470 |
|
|
2018
Q1 | $1K | Sell |
5
-70
| -93% | -$10.6K | ﹤0.01% | 7630 |
|
|
2017
Q4 | $10K | Buy |
+75
| New | +$9.5K | ﹤0.01% | 7007 |
|
|
2017
Q2 | – | Sell |
-5
| Closed | – | – | 7715 |
|
|
2017
Q1 | $0 | Sell |
5
-190
| -97% | -$21.2K | ﹤0.01% | 7689 |
|
|
2016
Q4 | $21K | Buy |
195
+163
| +509% | +$17.8K | ﹤0.01% | 6482 |
|
|
2016
Q3 | $4K | Sell |
32
-122
| -79% | -$12.7K | ﹤0.01% | 7192 |
|
|
2016
Q2 | $14K | Buy |
+154
| New | +$13.4K | ﹤0.01% | 6563 |
|
|
2015
Q4 | – | Sell |
-113
| Closed | -$14K | – | 8372 |
|
|
2015
Q3 | $14K | Sell |
113
-37
| -25% | -$4.94K | ﹤0.01% | 7008 |
|
|
2015
Q2 | $18K | Buy |
150
+49
| +49% | +$6.67K | ﹤0.01% | 6963 |
|
|
2015
Q1 | $27K | Buy |
+101
| New | +$20.8K | ﹤0.01% | 6654 |
|
Other funds holding CTSO
CM
UBS Group's CTSO Position: Q2 2026 in Review
UBS Group increased its Cytosorbents Corp (CTSO) stake by 14% in Q2 2026, buying an estimated $8.35K and bringing the position to 6,551 shares worth $49K. The position accounts for ﹤0.01% of the portfolio, ranked #7578.
UBS Group first reported a position in CTSO in Q1 2015 and has held it in 42 quarters since. The position peaked at $405K in Q2 2018. 47 funds tracked by Wall St. Rank hold CTSO as of Q2 2026.
- UBS Group held 6,551 shares of Cytosorbents Corp worth $49K as of Q2 2026.
- UBS Group bought 791 Cytosorbents Corp shares in Q2 2026, an estimated $8.35K.
- Cytosorbents Corp made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #7578 holding.
- UBS Group first reported a position in Cytosorbents Corp in Q1 2015 and has held it in 42 quarters since.
- UBS Group's Cytosorbents Corp position peaked at $405K in Q2 2018.
- 47 funds tracked by Wall St. Rank held Cytosorbents Corp as of Q2 2026.
Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.